Study of anti-müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 9, 2013, Pages 3785-3792

  Morel, Nathalie ^a,b   Bachelot, Anne ^a,b   Chakhtoura, Zeina ^a,b   Ghillani Dalbin, Pascale ^a,b   Amoura, Zahir ^a,b   Galicier, Lionel ^c   Alicier, Olivier ^e   Piette, Jean Charles ^a,b   Pourrat, Jacques ^f,g   Boutin, Du ^a,b   Sacre, Karim ^c,h   Kahn, Jean Emmanuel ⁱ   Duhaut, Pierre ^j   Farge, Dominique ^c,k   Francès, Camille ^o   Guettrot Imbert, Gaëlle ^d,g   Harle, Jean Robert ^c   Lambotte, Olivier ⁿ   Guern, Véronique Le ^o,p   Sène, Damien ^a,b   Trad, Salim ^h   Vidal, Elisabeth ^q   Sarrot Reynauld, Francoise ^q   Gompel, Anne ^l,m   Tanguy, Marie Laure ^b   Touraine, Philippe ^a,b   Lacorte, Jean Marc ^b   Costedoat Chalumeau, Nathalie ^a,b   more..

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

^f UNIVERSITÉ DE TOULOUSE   (France)

^g CHU RANGUEIL   (France)

^h BICHAT HOSPITAL   (France)

ⁱ FOCH HOSPITAL   (France)

^j AMIENS UNIVERSITY HOSPITAL   (France)

^k SAINT LOUIS HOSPITAL   (France)

^l HÔPITAL DE LA CONCEPTION   (France)

^m BICÊTRE HOSPITAL   (France)

ⁿ université Paris Cité   (France)

^o HÔPITAL AMBROISE PARÉ   (France)

^p Centre Hospitalier Régional Universitaire Dupuytren   (France)

^q HÔPITAL MICHALLON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; MUELLERIAN INHIBITING FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTI-MULLERIAN HORMONE; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREMENOPAUSE;

EID: 84883704753     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1235     Document Type: Article

References (30)

1. Appenzeller S, Blatyta PF, Costallat LT. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol Int. 2008;28:567-571.
2. Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119:366-369.
3. Clowse ME, Copland SC, Hsieh TC, et al. Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken). 2011;63: 1777-1781.
4. Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide.Astudy in 84 patients. J Rheumatol. 2002;29:2571-2576.
5. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13:673-678.
6. Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of ovarian failure and pregnancy outcome in patients with lupus ne phritis treated with intravenous cyclophosphamide pulse therapy. Lupus. 2004;13:569-574.
7. MedeirosMM,Silveira VA, Menezes AP, Carvalho RC. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res. 2001;34:1561-1568.
8. Baird DD, Steiner AZ. Anti-Mullerian hormone: a potential new tool in epidemiologic studies of female fecundability. Am J Epidemiol. 2012;175:245-249.
9. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95:170-175.
10. Meduri G, Massin N, Guibourdenche J, et al. Serum anti-Mullerian hormone expression in women with premature ovarian failure. Hum Reprod. 2007;22:117-123.
11. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8:331-341.
12. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One. 2011;6:e22024.
13. Clowse ME, Harward L, Criscione-Schreiber L, Pisetsky D, Copland S. Anti-Mullerian hormone: a better marker of ovarian damage from cyclophosphamide. Arthritis Rheum. 2012;64:1305-1310.
14. Aikawa NE, Sallum AM, Pereira RM, et al. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clin Exp Rheumatol. 2012;30:445-449.
15. Browne H, Armstrong A, Decherney A, et al. Assessment of ovarian function with anti-Mullerian hormone in systemic lupus erythematosus patients undergoing hematopoietic stem cell transplant. Fertil Steril. 2009;91(suppl 4):1529-1532.
16. Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus. 2011;20:1193-1197.
17. Marder W, McCune WJ, Wang L, et al. Adjunctive GnRH-A treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28:624-627.
18. Mok CC, Chan PT, To CH. Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013;65: 206-210.
19. Costedoat-Chalumeau N, Galicier L, Aumaitre O, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study) [published online ahead of print January 7, 2013]. Ann Rheum Dis. doi:10.1136/annrheumdis- 2012-202322.
20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
21. Seifer DB, Baker VL, Leader B. Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril. 2011;95:747-750.
22. La Marca A, Spada E, Grisendi V, et al. Normal serum anti-Mullerian hormone levels in the general female population and the relationship with reproductive history. Eur J Obstet Gynecol Reprod Biol. 2012;163:180-184.
23. Moncayo R, Moncayo HE. A new endocrinological and immunological syndrome in SLE: elevation of human chorionic gonadotropin and of antibodies directed against ovary and endometrium antigens. Lupus. 1995;4:39-45.
24. Pasoto SG, Viana VS, Mendonca BB, Yoshinari NH, Bonfa E. Anticorpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol. 1999;26: 1087-1093.
25. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008;90:395-400.
26. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle.HumReprod. 2006;21:3103-3107.
27. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF 3rd. Association of anti-mullerian hormone levels with obesity in late reproductive-Age women. Fertil Steril. 2007;87:101-106.
28. Su HI, Sammel MD, Freeman EW, Lin H, DeBlasis T, Gracia CR. Body size affects measures of ovarian reserve in late reproductive age women. Menopause. 2008;15:857-861.
29. Janse F, Donnez J, Anckaert E, de Jong FH, Fauser BC, Dolmans MM. Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment. J Clin Endocrinol Metab. 2011;96:1136-1144.
30. Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab. 2011;96:3864-3872.